Evolus, Inc. (NASDAQ:EOLS) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC increased its stake in shares of Evolus, Inc. (NASDAQ:EOLS) by 0.3% in the fourth quarter, HoldingsChannel.com reports. The firm owned 1,214,590 shares of the company’s stock after buying an additional 3,969 shares during the period. Geode Capital Management LLC’s holdings in Evolus were worth $13,412,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the stock. KBC Group NV purchased a new position in shares of Evolus during the fourth quarter worth $49,000. IFP Advisors Inc grew its position in Evolus by 17,440.7% in the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock valued at $52,000 after acquiring an additional 4,709 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in Evolus during the fourth quarter worth about $106,000. Quantbot Technologies LP acquired a new stake in shares of Evolus during the fourth quarter worth about $118,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Evolus by 10.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the company’s stock valued at $148,000 after purchasing an additional 1,291 shares during the period. Institutional investors and hedge funds own 90.69% of the company’s stock.

Insider Buying and Selling

In other news, insider David Moatazedi sold 6,251 shares of Evolus stock in a transaction dated Thursday, March 27th. The stock was sold at an average price of $12.40, for a total transaction of $77,512.40. Following the sale, the insider now owns 508,619 shares in the company, valued at approximately $6,306,875.60. The trade was a 1.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Sandra Beaver sold 8,996 shares of the company’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total value of $119,286.96. Following the completion of the sale, the chief financial officer now directly owns 173,583 shares of the company’s stock, valued at approximately $2,301,710.58. This trade represents a 4.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 60,575 shares of company stock worth $794,369 over the last 90 days. 6.10% of the stock is owned by insiders.

Evolus Stock Down 3.8 %

Evolus stock opened at $10.38 on Tuesday. The stock’s fifty day moving average is $12.54 and its two-hundred day moving average is $13.05. The stock has a market cap of $660.03 million, a PE ratio of -11.41 and a beta of 0.97. Evolus, Inc. has a 1-year low of $8.67 and a 1-year high of $17.82. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23.

Analyst Upgrades and Downgrades

EOLS has been the topic of several recent research reports. BTIG Research initiated coverage on shares of Evolus in a research note on Thursday, April 17th. They set a “buy” rating and a $21.00 target price on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price objective on shares of Evolus in a research report on Wednesday, April 9th. HC Wainwright reiterated a “buy” rating and issued a $27.00 target price on shares of Evolus in a report on Thursday, April 10th. Finally, Barclays upped their price target on Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Evolus has a consensus rating of “Buy” and a consensus price target of $23.75.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.